Literature DB >> 18519489

Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study.

Roger Kurlan1, Dwight Johnson, Edward L Kaplan.   

Abstract

OBJECTIVE: If pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections is a unique clinical entity, we hypothesized that children meeting diagnostic criteria would have more clinical exacerbations temporally linked to bona fide group A beta-hemolytic streptococcus infection than matched control subjects (chronic tic and/or obsessive-compulsive disorder with no known temporal relationship to group A beta-hemolytic streptococcus infection). PATIENTS AND METHODS: Subjects included 40 matched pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections case-control pairs who were prospectively evaluated with intensive laboratory testing for group A beta-hemolytic streptococcus and clinical measures for an average of 2 years. Additional testing occurred at the time of any clinical exacerbations or illness. Laboratory personnel were blinded to case or control status and clinical (exacerbation or not) condition. Clinical raters were blinded to the results of laboratory tests.
RESULTS: The cases had a higher clinical exacerbation rate and a higher bona fide group A beta-hemolytic streptococcus infection rate than the control group. Only 5 of 64 exacerbations were temporally associated (within 4 weeks) with a group A beta-hemolytic streptococcus infection, and all occurred in cases. The number (5.0) was significantly higher than the number that would be expected by chance alone (1.6). Yet, >/=75% of the clinical exacerbations in cases had no observable temporal relationship to group A beta-hemolytic streptococcus infection.
CONCLUSIONS: Patients who fit published criteria for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections seem to represent a subgroup of those with chronic tic disorders and obsessive-compulsive disorder who may be vulnerable to group A beta-hemolytic streptococcus infection as a precipitant of neuropsychiatric symptom exacerbations. Group A beta-hemolytic streptococcus infection is not the only or even the most common antecedent event associated with exacerbations for these patients. Additional intensive studies are needed to determine whether there is clinical or scientific evidence to support separating out subgroups of tic disorder and/or obsessive-compulsive disorder patients based on specific symptom precipitants.

Entities:  

Mesh:

Year:  2008        PMID: 18519489     DOI: 10.1542/peds.2007-2657

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  40 in total

Review 1.  Obsessive-Compulsive Disorder: Autoimmunity and Neuroinflammation.

Authors:  Mona Gerentes; Antoine Pelissolo; Krishnamoorthy Rajagopal; Ryad Tamouza; Nora Hamdani
Journal:  Curr Psychiatry Rep       Date:  2019-08-01       Impact factor: 5.285

Review 2.  Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: an overview.

Authors:  S Esposito; S Bianchini; E Baggi; M Fattizzo; D Rigante
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-24       Impact factor: 3.267

3.  Immunoglobulin A Dysgammaglobulinemia Is Associated with Pediatric-Onset Obsessive-Compulsive Disorder.

Authors:  Kyle Williams; Leah Shorser-Gentile; Suraj Sarvode Mothi; Noah Berman; Mark Pasternack; Daniel Geller; Jolan Walter
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-03-20       Impact factor: 2.576

Review 4.  Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V.

Authors:  James F Leckman; Damiaan Denys; H Blair Simpson; David Mataix-Cols; Eric Hollander; Sanjaya Saxena; Euripedes C Miguel; Scott L Rauch; Wayne K Goodman; Katharine A Phillips; Dan J Stein
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

5.  Linkage analysis of Tourette syndrome in a large Utah pedigree.

Authors:  Stacey Knight; Hilary Coon; Michael Johnson; Mark F Leppert; Nicola J Camp; William M McMahon
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

6.  On the connection between autoimmunity, tic disorders and obsessive-compulsive disorders: a meta-analysis on anti-streptolysin O titres.

Authors:  Marco Pozzi; Paolo Pellegrino; Carla Carnovale; Valentina Perrone; Stefania Antoniazzi; Cristiana Perrotta; Sonia Radice; Emilio Clementi
Journal:  J Neuroimmune Pharmacol       Date:  2014-08-05       Impact factor: 4.147

7.  Streptococcal upper respiratory tract infections and psychosocial stress predict future tic and obsessive-compulsive symptom severity in children and adolescents with Tourette syndrome and obsessive-compulsive disorder.

Authors:  Haiqun Lin; Kyle A Williams; Liliya Katsovich; Diane B Findley; Heidi Grantz; Paul J Lombroso; Robert A King; Debra E Bessen; Dwight Johnson; Edward L Kaplan; Angeli Landeros-Weisenberger; Heping Zhang; James F Leckman
Journal:  Biol Psychiatry       Date:  2009-10-14       Impact factor: 13.382

8.  Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens.

Authors:  Mauro Bombaci; Renata Grifantini; Marirosa Mora; Valerio Reguzzi; Roberto Petracca; Eva Meoni; Sergio Balloni; Chiara Zingaretti; Fabiana Falugi; Andrea G O Manetti; Immaculada Margarit; James M Musser; Francesco Cardona; Graziella Orefici; Guido Grandi; Giuliano Bensi
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

Review 9.  Immunopathogenic mechanisms in tourette syndrome: A critical review.

Authors:  Davide Martino; Russell C Dale; Donald L Gilbert; Gavin Giovannoni; James F Leckman
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

Review 10.  Immune-mediated animal models of Tourette syndrome.

Authors:  Mady Hornig; W Ian Lipkin
Journal:  Neurosci Biobehav Rev       Date:  2013-01-10       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.